Global MedTech Conference 2025

On July 17, 2025, the 2nd Global MedTech Conference (Global MedTech Conference 2025) was held at Zhongguancun Exhibition Center in Beijing. Centered on key fields including artificial intelligence, brain-computer interfaces and high-end domestic medical devices, the conference featured in-depth exchanges revolving around the core theme of "Technology Empowerment + Translation and Implementation". The conference unveiled the *2025 Medical Device BD White Paper* and launched the "Global Medical Technology Innovation Awards Series", sending a clear signal: China’s medical technology is entering a new phase of evolution from "isolated breakthroughs" to "systematic capabilities".

Policy-driven and Industrial Collaboration: The Emergence of a "Platform Logic" for Innovation Implementation

At the opening of the conference, Liu Hui, Director of the Beijing Medical and Health Science and Technology Development Center, stated in her address that amid the vigorous global development of medical technology, Beijing’s medical and health industry has exceeded 1.06 trillion yuan in scale. The number of innovative medical device registrations has ranked first nationwide for three consecutive years. Beijing is accelerating the development of an industrial ecosystem anchored by the "32 Policy Measures", supported by streamlined review efficiency and real-world scenario deployment, to advance the capital’s medical technology toward global leadership.

Liu Hui, Director of the Beijing Medical and Health Science and Technology Development Center

Pu Fang, Professor at the School of Biological Science and Medical Engineering, Beihang University, and Vice President of China Assistive Devices and Technology Association, said the key to advancing medical technology implementation lies in "cross-border ecosystem building". Scientific research is abundant in papers and patents, yet the real challenge is embedding product design into clinical workflows. Universities, research institutes, clinical resources and the industry need to collaborate to empower patients and clinicians through technological innovation.

Subsequently, the conference held an on-site award ceremony for multiple enterprises honored at the end of last year, and newly presented the "2025 Global Medical Technology Innovation Awards Series". The grand awards are announced! 11 awards in total! The 2025 Global Medical Technology Innovation Grand Awards

Meanwhile, Zhao Qing, Founder of Siyu MedTech, officially released the 2025 Global MedTech Top100 list. The Global MedTech Top100 List is out! 12 Chinese enterprises are on the ranking! 2025 Global MedTech TOP100

The 2025 Medical Device BD White Paper was also launched. Full text available for free download! The *Medical Device BD White Paper* is officially released

From policy guidance and award mechanisms to the systematic white paper, a complete industrial framework centered on "starting from clinical practice and focusing on translation" is taking shape. Medical technology is entering a new stage shifting from isolated breakthroughs to structured implementation.

Diverse Implementation Pathways for Medical Technology: From Institutional Support to Case Studies

For industrial strategies to be truly translated between technologies and real-world scenarios, practical experience and pathway exploration from frontline experts remain essential.

Ren Zhijun, Section Chief of the Beijing Medical Device Evaluation and Inspection Center, introduced the latest practice of Beijing’s "smart review" mechanism, including pre-review of registration documents, pre-review of supplementary materials and key project management services, aiming to improve enterprises’ registration efficiency from the source. She emphasized that a clinical-value-oriented design closed loop is the fundamental approach to accelerate product registration at present.

Pang Yu, Director of the Bacteriology and Immunology Laboratory and Director of the Research Department at Beijing Chest Hospital, Capital Medical University, shared the hospital’s achievements in diagnostic reagents and novel vaccines using tuberculosis translational research as an example. He pointed out that high-quality translational outcomes usually stem from deep integration of long-term accumulated patient resources, basic research and scenario demands within hospitals.

Zhao Yangguang, Deputy Director of the Bio-Technology Department, Cloud Computing and Big Data Research Institute, China Academy of Information and Communications Technology, systematically elaborated on the definition, registration pathways and verification mechanisms of AI medical devices. He stressed that AI medical devices are more than just "algorithm applications"; they represent full-lifecycle engineering covering demand analysis, data compliance, clinical adaptation and system iteration.

Zuo Nianming, Researcher at the Institute of Automation, Chinese Academy of Sciences and Director of the Brain Network Group Research Center, delivered a presentation themed "Applications of Wearable Brain-Computer Interfaces in Mental Disorders", demonstrating new possibilities for objective detection and intervention for depression, anxiety and other illnesses. He noted that the advancement of brain interfaces hinges on low invasiveness, high signal-to-noise ratio, high-precision encoding and decoding, and wearable integration. Relevant products are entering preliminary clinical trials.

Wang Zaicun, Chief Analyst of the Medical Devices and Services Industry at CITIC Securities, believes the medical equipment sector has shown signs of bottom recovery, and the high-value consumables sector is ushering in a window of policy optimization. He stated that enterprises’ capacity to launch high-volume new products and achieve internationalization are core variables for future valuation recovery and investment value.

Liu Shenghui, Chief Scientific Officer (CSO) of Sinovision, took CT imaging equipment as an example to systematically illustrate how the company broke through bottlenecks in core components through independent innovation, clinical adaptive development and global market layout, realizing the domestic substitution path "from manufacturing to products and then to solutions".

Ye Jing, Co-Chief Pharmaceutical Analyst of Northeast Securities, pointed out from the primary market perspective that innovative medical devices are in a consolidation phase after a new round of "structural compression". Regulatory coordination, medical insurance linkage and international competitiveness will determine whether a "positive investment cycle" can be rebuilt in the future.

10 Innovative Enterprises Mapping the Future Landscape

Technology implementation is never merely about concepts or assumptions. Centered on specific products, systematic capabilities and scenario demands, enterprise representatives depicted the roadmap for translating technology into reality with practical cases.

Gong Mengchun, Senior Vice President and Chief Medical Officer of Shenzhou Medical, stated that Shenzhou Medical has proposed a "dual-engine" framework for coordinated advancement of a multimodal data platform and medical large models. Leveraging general data models, structured electronic medical record governance and semantic coding technologies, the framework supports AI clinical research and auxiliary decision-making for major diseases such as kidney disease. The centralized kidney disease database built nationwide by the company has covered 30 million electronic medical records, and the team is exploring deep integration of privacy-preserving mechanisms into large model training workflows.

Fan Xiangmin, Chairman of Zhongke Ruiyi and Researcher at the Institute of Software, Chinese Academy of Sciences, introduced that its AI + neuroscience platform focuses on quantitative screening and precise intervention for neuropsychiatric disorders, building a digital therapeutics pathway running through "symptom scales — behavior recognition — brain function remodeling". He noted that traditional neurological diagnosis and treatment has long relied on subjective symptom scoring and lacks standardized measurement tools. With AI vision and eye-tracking technologies, Zhongke Ruiyi has developed multimodal "digital rulers" for motor function, cognitive function and more. These tools have been deployed in over 400 clinical institutions and used more than one million times cumulatively.

Zhang Jie, Co-founder and COO of Vision Perception, focused on the application of AI ultrasound in musculoskeletal diseases, demonstrating how its three-dimensional assessment system covering "muscle status + bone surface status + motion trajectory" reshapes the promotion process of minimally invasive outpatient procedures. Its AI ultrasound platform has completed segmentation and real-time feedback for six major joints and the cervical region, boasting an image structure recognition rate above 93%, and is forming a closed loop spanning teaching, diagnosis and treatment. Zhang Jie pointed out that ultrasound-guided musculoskeletal treatment is a critical pathway for modernizing precise traditional Chinese medicine diagnosis and treatment based on structural visualization and quantifying rehabilitation assessment.

Zhang Jizhuang, CTO of Raydiant Biotech, outlined the development of pulsed electric field ablation technology. From the first-generation "reversible electroporation" to the third-generation "nanoknife", it has gradually realized a novel treatment mode with higher tissue selectivity and lower intraoperative trauma. He said pulsed electric fields show potential as a "platform energy technology" across multiple fields including oncology, electrophysiology and metabolic diseases. Raydiant Biotech’s nanoknife product has achieved an ablation rate of over 80% in complex liver cancer cases, making it the first relevant medical device in China to obtain a Class III registration certificate.

Zhang Nan, COO of Touche Future, stated that China faces a shortage of 110,000 pathologists, and the AI pathological diagnosis system built by the company holds tremendous potential. Its developed software improves diagnostic accuracy and efficiency, achieving global technological innovation breakthroughs. In terms of data, the iPad-based annotation system has completed more than 2 billion high-precision annotations, lifting annotation efficiency by at least 10 times. For algorithms, convolutional neural networks and Vision Transformer technologies are adopted to develop image segmentation algorithms that deliver pixel-level malignancy probability scoring on whole-slide images, covering dozens of organ groups. In computing power, the self-developed distributed microservice architecture supports seamless scaling of machines and GPUs, completing intelligent analysis of GB-level slides within 20 seconds to meet daily diagnostic needs of pathology departments.

Hu Zhiyuan, Founder and Chairman of Zhongke Natai, emphasized that this diagnostic platform enriches and identifies extremely rare circulating tumor cells (CTCs) in peripheral blood via nanoprobes, delivering higher sensitivity and multi-cancer screening capacity. This technology has completed multiple clinical collaborations with Peking Union Medical College Hospital, National Cancer Center Hospital and Peking University Third Hospital. It has been included in clinical diagnosis and treatment guidelines, formally added to Beijing’s medical catalog in 2025, and can be used for monitoring recurrence and metastasis of solid tumors, playing a key role in treatment decision-making for complex lesions such as pulmonary ground-glass nodules and thyroid nodules.

Zhang Jihong, CEO of Ice Crystal Intelligence, noted that interventional surgery scenarios impose extremely high requirements for "intraoperative imaging visualization". The cardiac interventional ultrasound platform developed by the company uses miniature probes for real-time intracardiac imaging, and improves image quality and surgical navigation capabilities via AI algorithms. It has completed clinical applications in multiple hospitals. Zhang Jihong stressed that image visualization and intraoperative recording capabilities serve dual purposes: boosting surgeons’ learning efficiency and lowering intraoperative risks.

Meng Xi, COO of Renuo Medical, spoke from the perspective of a medical device manufacturer and highlighted that "informatization of surgical instruments" represents a current technical shortfall in domestic substitution. The host-free wireless ultrasonic scalpel launched by Renuo solves the problem of tangled cables and complicated connections on operating tables during minimally invasive surgery, and achieves miniaturization at the mainboard chip level and docking with analog system data interfaces. He said intelligence at the device layer is a vital step toward real-world deployment of AI surgical systems.

Qin Lan, Founder, Chairman and General Manager of Strong Medical Robotics, reviewed her decade-long entrepreneurial journey in neurointerventional robots. She emphasized that the core value of the catheter shaping robot lies in "eliminating operator variability". An automatic procedure planning system has been built based on China’s structural cerebrovascular disease database and incorporated into national clinical guidelines. Relevant products have obtained Class III innovative medical device certification and are supporting standardization and wider adoption of neurointerventional procedures.

Zhou Mingchuan, Founder and CTO of Dvision Medical, shared the R&D pathway of ophthalmic surgical robots in minimally invasive micromanipulation, stating that "retinal puncture + OCT navigation" constitutes the key scenario for ophthalmic robots. After addressing the lack of intraocular force sensing and visual feedback, Dvision’s robot achieves submillimeter-level control and autonomous trajectory tracing, and enhances surgical precision through light spot feedback and inter-frame deformation estimation. Its goal is to deliver stability and consistency far exceeding manual operation for high-difficulty scenarios such as retinal artery occlusion and gene injection.

Technology routes are becoming clearer and industrial directions more focused. Medical technology is shifting from "whether it can be achieved" to "how to make it commercially viable". As key links connecting clinical practice, scientific research and the market, enterprises are playing an increasingly central role in the translation logic.

The Destination of Medical Technology Lies Not in Laboratories, but in Pathway Capabilities

From regulatory mechanisms and enterprise cases to research logic and commercial closed loops, the 2nd Global MedTech Conference clearly demonstrates that medical technology innovation has moved from "whether to innovate" to "how to implement", with the core being clarity of implementation pathways. What truly drives industrial progress is the synergistic resonance among four links: regulation, scientific research, clinical practice and the market. Medical technology has entered an era of "implementation competitiveness". The decisive factor has changed — whoever can complete the translation closed loop will seize the initiative in this medical technology race.